Literature DB >> 21956743

Comprehensive structural and functional characterization of Mycobacterium tuberculosis UDP-NAG enolpyruvyl transferase (Mtb-MurA) and prediction of its accurate binding affinities with inhibitors.

B Babajan1, M Chaitanya, C Rajsekhar, D Gowsia, P Madhusudhana, M Naveen, Suresh Kumar Chitta, C M Anuradha.   

Abstract

Tuberculosis (TB) remains the most frequent and important infectious disease causing morbidity and death in the world. One third of the world's population is infected with Mycobacterium tuberculosis (Mtb), the etiologic agent of TB. The bacterial enzyme MurA catalyzes the transfer of enolpyruvate from phosphoenolpyruvate (PEP) to uridine diphospho-N-acetylglucosamine (UNAG), which is the first committed step of bacterial cell wall biosynthesis. In this work, 3D structure model of Mtb-MurA enzyme has been developed for the first time by homology modeling and molecular dynamics simulation techniques. Multiple sequence alignment and 3D structure model provided the putative substrate binding pocket of Mtb-MurA with respect to E. coli MurA. This analysis was helpful in identifying the binding sites and molecular function of the MurA homologue. Molecular docking study was performed on this 3D structure model, using different classes of inhibitors like fosfomycin, cyclic disulfide analog RWJ-3981, pyrazolopyrimidine analog RWJ-110192, purine analog RWJ-140998, 5-sulfonoxy-anthranilic acid derivatives T6361, T6362 and the results showed that the 5-sulfonoxyanthranilic acid derivatives showed the best interaction compared to other inhibitors. We also designed new efficient analogs of T6361 and T6362 which showed even better interaction with Mtb-MurA than the parental 5-sulfonoxy-anthranilic acid derivatives. Further the comparative molecular electrostatic potential and cavity depth analysis of Mtb-MurA suggested several important differences in its substrate and inhibitor binding pocket. Such differences could be exploited in the future for designing a more specific inhibitor for Mtb-MurA enzyme.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21956743     DOI: 10.1007/s12539-011-0100-y

Source DB:  PubMed          Journal:  Interdiscip Sci        ISSN: 1867-1462            Impact factor:   2.233


  4 in total

Review 1.  Recent Progress in the Development of Novel Mycobacterium Cell Wall Inhibitor to Combat Drug-Resistant Tuberculosis.

Authors:  Tafere Mulaw Belete
Journal:  Microbiol Insights       Date:  2022-05-23

Review 2.  Cell wall peptidoglycan in Mycobacterium tuberculosis: An Achilles' heel for the TB-causing pathogen.

Authors:  Arundhati Maitra; Tulika Munshi; Jess Healy; Liam T Martin; Waldemar Vollmer; Nicholas H Keep; Sanjib Bhakta
Journal:  FEMS Microbiol Rev       Date:  2019-09-01       Impact factor: 16.408

3.  Ursolic acid rich Ocimum sanctum L leaf extract loaded nanostructured lipid carriers ameliorate adjuvant induced arthritis in rats by inhibition of COX-1, COX-2, TNF-α and IL-1: Pharmacological and docking studies.

Authors:  Aftab Ahmad; Mohammed F Abuzinadah; Huda M Alkreathy; Babajan Banaganapalli; Mohd Mujeeb
Journal:  PLoS One       Date:  2018-03-20       Impact factor: 3.240

4.  sncRNA-1 Is a Small Noncoding RNA Produced by Mycobacterium tuberculosis in Infected Cells That Positively Regulates Genes Coupled to Oleic Acid Biosynthesis.

Authors:  Fatma S Coskun; Shashikant Srivastava; Prithvi Raj; Igor Dozmorov; Serkan Belkaya; Smriti Mehra; Nadia A Golden; Allison N Bucsan; Moti L Chapagain; Edward K Wakeland; Deepak Kaushal; Tawanda Gumbo; Nicolai S C van Oers
Journal:  Front Microbiol       Date:  2020-07-28       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.